AVI BioPharma, Inc. (NASDAQ:AVII)
CAPS Rating:
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.
The World's Greatest Investing Community
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Anti-sense holds potential to provide potent anti-viral agents. Data on clinical impact of morpholinos on DMD due before the end of the year. Large government contracts anticipated in the near future. Early studies show their flu drugs more potent then Tamiflu.